Abstract
There are still so-called unmet needs in the treatment of epithelial and cutaneous lesions. Mucositis, ocular lesions, chronic skin wounds represent typical examples. These pathologies do not yet afford a satisfactory treatment. In particular chronic wounds represent a major health care burden, likely to increase as the population ages. Healing of epithelial and cutaneous lesions progresses through a complex cascade of events starting with the secretion in the local environment of a pool of growth factors, cytokines and proteins from the serum and degranulating platelets. Recently platelet lysate (PL), a hemoderivative obtained by platelet destruction by freeze-thawing of a platelet rich plasma (PRP) sample in the presence of an anticoagulant agent, has proved capable of promoting the healing of buccal and corneal lesions. Since the efficacy of growth factors (GFs) critically depends on the way they are made available to the injured tissue, the development of suitable therapeutic vehicles is of paramount importance to release GFs according to the repairing requirements. The present work focuses on the development and testing of few such formulations, in particular a mucoadhesive gel and an in situ gelling buccal spray for the treatment of oral mucositis, and a thermosensitive eye drop solution for corneal lesions. Besides technological characterization, the formulations have been preliminarily screened with an ELISA assay, a cell proliferation test and an in vitro wound healing test. Some formulations have been used in early clinical trials.
| Original language | English |
|---|---|
| Pages (from-to) | 18-31 |
| Number of pages | 14 |
| Journal | Current Drug Delivery |
| Volume | 10 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- Buccal and corneal lesions
- Cell culture models
- Drug delivery systems
- Platelet lysate
- Wound healing
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
New therapeutic platforms for the treatment of epithelial and cutaneous lesions. / Caramella, Carla M.; Sandri, Giuseppina; Rossi, Silvia; Mori, Michela; Bonferoni, Maria Cristina; Ferrari, Franca; Del Fante, Claudia; Perotti, Cesare.
In: Current Drug Delivery, Vol. 10, No. 1, 2013, p. 18-31.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - New therapeutic platforms for the treatment of epithelial and cutaneous lesions
AU - Caramella, Carla M.
AU - Sandri, Giuseppina
AU - Rossi, Silvia
AU - Mori, Michela
AU - Bonferoni, Maria Cristina
AU - Ferrari, Franca
AU - Del Fante, Claudia
AU - Perotti, Cesare
PY - 2013
Y1 - 2013
N2 - There are still so-called unmet needs in the treatment of epithelial and cutaneous lesions. Mucositis, ocular lesions, chronic skin wounds represent typical examples. These pathologies do not yet afford a satisfactory treatment. In particular chronic wounds represent a major health care burden, likely to increase as the population ages. Healing of epithelial and cutaneous lesions progresses through a complex cascade of events starting with the secretion in the local environment of a pool of growth factors, cytokines and proteins from the serum and degranulating platelets. Recently platelet lysate (PL), a hemoderivative obtained by platelet destruction by freeze-thawing of a platelet rich plasma (PRP) sample in the presence of an anticoagulant agent, has proved capable of promoting the healing of buccal and corneal lesions. Since the efficacy of growth factors (GFs) critically depends on the way they are made available to the injured tissue, the development of suitable therapeutic vehicles is of paramount importance to release GFs according to the repairing requirements. The present work focuses on the development and testing of few such formulations, in particular a mucoadhesive gel and an in situ gelling buccal spray for the treatment of oral mucositis, and a thermosensitive eye drop solution for corneal lesions. Besides technological characterization, the formulations have been preliminarily screened with an ELISA assay, a cell proliferation test and an in vitro wound healing test. Some formulations have been used in early clinical trials.
AB - There are still so-called unmet needs in the treatment of epithelial and cutaneous lesions. Mucositis, ocular lesions, chronic skin wounds represent typical examples. These pathologies do not yet afford a satisfactory treatment. In particular chronic wounds represent a major health care burden, likely to increase as the population ages. Healing of epithelial and cutaneous lesions progresses through a complex cascade of events starting with the secretion in the local environment of a pool of growth factors, cytokines and proteins from the serum and degranulating platelets. Recently platelet lysate (PL), a hemoderivative obtained by platelet destruction by freeze-thawing of a platelet rich plasma (PRP) sample in the presence of an anticoagulant agent, has proved capable of promoting the healing of buccal and corneal lesions. Since the efficacy of growth factors (GFs) critically depends on the way they are made available to the injured tissue, the development of suitable therapeutic vehicles is of paramount importance to release GFs according to the repairing requirements. The present work focuses on the development and testing of few such formulations, in particular a mucoadhesive gel and an in situ gelling buccal spray for the treatment of oral mucositis, and a thermosensitive eye drop solution for corneal lesions. Besides technological characterization, the formulations have been preliminarily screened with an ELISA assay, a cell proliferation test and an in vitro wound healing test. Some formulations have been used in early clinical trials.
KW - Buccal and corneal lesions
KW - Cell culture models
KW - Drug delivery systems
KW - Platelet lysate
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=84875337574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875337574&partnerID=8YFLogxK
U2 - 10.2174/1567201811310010005
DO - 10.2174/1567201811310010005
M3 - Article
C2 - 22998040
AN - SCOPUS:84875337574
VL - 10
SP - 18
EP - 31
JO - Current Drug Delivery
JF - Current Drug Delivery
SN - 1567-2018
IS - 1
ER -